Date of first authorisation/renewal of the authorisationStart typing to retrieve search suggestions. Statins can also raise "good" cholesterol (called HDL).
If treatment with systemic fusidic acid is necessary, atorvastatin treatment should be discontinued throughout the duration of the fusidic acid treatment (see section 4.4).Although interaction studies with atorvastatin and colchicine have not been conducted, cases of myopathy have been reported with atorvastatin co-administered with colchicine, and caution should be exercised when prescribing atorvastatin with colchicine.When multiple doses of digoxin and 10 mg atorvastatin were co-administered, steady-state digoxin concentrations increased slightly.
When compared to pravastatin the effects of atorvastatin were statistically significant (p=0.02).
16-fold in CHepatic uptake of all HMG-CoA reductase inhibitors including atorvastatin, involves the OATP1B1 transporter.
Because of the potential for serious adverse reactions, women taking Lipitor should not breast-feed their infants (see section 4.3). At atorvastatin doses exceeding 40 mg, clinical monitoring of these patients is recommendedDarunavir 300 mg BID/ Ritonavir 100 mg BID, 9 days Fosamprenavir 700 mg BID/ Ritonavir 100 mg BID, 14 days The dose of atorvastatin should not exceed a daily dose of 20 mg during co-administration with products containing elbasvir or grazoprevir.The dose of atorvastatin should not exceed a daily dose of 20 mg during co-administration with products containing letermovir.Concomitant intake of large quantities of grapefruit juice and atorvastatin is not recommended.After initiation or following dose adjustments of diltiazem, appropriate clinical monitoring of these patients is recommended.Lower maximum dose and clinical monitoring of these patients is recommended.Antacid suspension of magnesium and aluminium hydroxides, 30 mL QID, 17 daysIf co-administration cannot be avoided, simultaneous co-administration of atorvastatin with rifampin is recommended, with clinical monitoring.Lower starting dose and clinical monitoring of these patients is recommended.Lower starting dose and clinical monitoring of these patients is recommended.Lower starting dose and clinical monitoring of these patients is recommended. Cohort A included 15 children, 6 to 12 years of age and at Tanner Stage 1. A CK level should be measured before starting statin treatment in the following situations:- Personal or familial history of hereditary muscular disorders- Previous history of muscular toxicity with a statin or fibrate- Previous history of liver disease and/or where substantial quantities of alcohol are consumed- In elderly (age > 70 years), the necessity of such measurement should be considered, according to the presence of other predisposing factors for rhabdomyolysis- Situations where an increase in plasma levels may occur, such as interactions (see section 4.5) and special populations including genetic subpopulations (see section 5.2)In such situations, the risk of treatment should be considered in relation to possible benefit, and clinical monitoring is recommended.If CK levels are significantly elevated (> 5 times ULN) at baseline, treatment should not be started.Creatine kinase (CK) should not be measured following strenuous exercise or in the presence of any plausible alternative cause of CK increase as this makes value interpretation difficult. If possible, alternative (non-interacting) therapies should be considered instead of these medicinal products.In cases where co-administration of these medicinal products with atorvastatin is necessary, the benefit and the risk of concurrent treatment should be carefully considered. The atorvastatin dose was permitted to be doubled if a subject had not attained target LDL-C of < 3.35 mmol/L at Week 4 and if atorvastatin was well tolerated. Treatment with atorvastatin 80 mg/day increased the time to occurrence of the combined primary endpoint, defined as death from any cause, nonfatal MI, resuscitated cardiac arrest, or angina pectoris with evidence of myocardial ischaemia requiring hospitalization, indicating a risk reduction by 16% (p=0.048).
3. Atorvastatin is effective in reducing LDL-C in patients with homozygous familial hypercholesterolaemia, a population that has not usually responded to lipid-lowering medicinal products.Atorvastatin has been shown to reduce concentrations of total-C (30% - 46%), LDL-C (41% - 61%), apolipoprotein B (34% - 50%), and triglycerides (14% - 33%) while producing variable increases in HDL-C and apolipoprotein A1 in a dose response study.
A favourable trend was observed regarding the mortality rate (82 deaths in the placebo group vs. 61 deaths in the atorvastatin group, p=0.0592).In the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study, the effect of atorvastatin 80 mg daily or placebo on stroke was evaluated in 4731 patients who had a stroke or transient ischemic attack (TIA) within the preceding 6 months and no history of coronary heart disease (CHD). Lipitor is used to lower lipids known as cholesterol and triglycerides in the blood when a low fat diet and life style changes on their own have failed.
In rats, plasma concentrations of atorvastatin are similar to those in milk.
If treatment with systemic fusidic acid is necessary, atorvastatin treatment should be discontinued throughout the duration of the fusidic acid treatment (see section 4.4).Although interaction studies with atorvastatin and colchicine have not been conducted, cases of myopathy have been reported with atorvastatin co-administered with colchicine, and caution should be exercised when prescribing atorvastatin with colchicine.When multiple doses of digoxin and 10 mg atorvastatin were co-administered, steady-state digoxin concentrations increased slightly.
When compared to pravastatin the effects of atorvastatin were statistically significant (p=0.02).
16-fold in CHepatic uptake of all HMG-CoA reductase inhibitors including atorvastatin, involves the OATP1B1 transporter.
Because of the potential for serious adverse reactions, women taking Lipitor should not breast-feed their infants (see section 4.3). At atorvastatin doses exceeding 40 mg, clinical monitoring of these patients is recommendedDarunavir 300 mg BID/ Ritonavir 100 mg BID, 9 days Fosamprenavir 700 mg BID/ Ritonavir 100 mg BID, 14 days The dose of atorvastatin should not exceed a daily dose of 20 mg during co-administration with products containing elbasvir or grazoprevir.The dose of atorvastatin should not exceed a daily dose of 20 mg during co-administration with products containing letermovir.Concomitant intake of large quantities of grapefruit juice and atorvastatin is not recommended.After initiation or following dose adjustments of diltiazem, appropriate clinical monitoring of these patients is recommended.Lower maximum dose and clinical monitoring of these patients is recommended.Antacid suspension of magnesium and aluminium hydroxides, 30 mL QID, 17 daysIf co-administration cannot be avoided, simultaneous co-administration of atorvastatin with rifampin is recommended, with clinical monitoring.Lower starting dose and clinical monitoring of these patients is recommended.Lower starting dose and clinical monitoring of these patients is recommended.Lower starting dose and clinical monitoring of these patients is recommended. Cohort A included 15 children, 6 to 12 years of age and at Tanner Stage 1. A CK level should be measured before starting statin treatment in the following situations:- Personal or familial history of hereditary muscular disorders- Previous history of muscular toxicity with a statin or fibrate- Previous history of liver disease and/or where substantial quantities of alcohol are consumed- In elderly (age > 70 years), the necessity of such measurement should be considered, according to the presence of other predisposing factors for rhabdomyolysis- Situations where an increase in plasma levels may occur, such as interactions (see section 4.5) and special populations including genetic subpopulations (see section 5.2)In such situations, the risk of treatment should be considered in relation to possible benefit, and clinical monitoring is recommended.If CK levels are significantly elevated (> 5 times ULN) at baseline, treatment should not be started.Creatine kinase (CK) should not be measured following strenuous exercise or in the presence of any plausible alternative cause of CK increase as this makes value interpretation difficult. If possible, alternative (non-interacting) therapies should be considered instead of these medicinal products.In cases where co-administration of these medicinal products with atorvastatin is necessary, the benefit and the risk of concurrent treatment should be carefully considered. The atorvastatin dose was permitted to be doubled if a subject had not attained target LDL-C of < 3.35 mmol/L at Week 4 and if atorvastatin was well tolerated. Treatment with atorvastatin 80 mg/day increased the time to occurrence of the combined primary endpoint, defined as death from any cause, nonfatal MI, resuscitated cardiac arrest, or angina pectoris with evidence of myocardial ischaemia requiring hospitalization, indicating a risk reduction by 16% (p=0.048).
3. Atorvastatin is effective in reducing LDL-C in patients with homozygous familial hypercholesterolaemia, a population that has not usually responded to lipid-lowering medicinal products.Atorvastatin has been shown to reduce concentrations of total-C (30% - 46%), LDL-C (41% - 61%), apolipoprotein B (34% - 50%), and triglycerides (14% - 33%) while producing variable increases in HDL-C and apolipoprotein A1 in a dose response study.
A favourable trend was observed regarding the mortality rate (82 deaths in the placebo group vs. 61 deaths in the atorvastatin group, p=0.0592).In the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study, the effect of atorvastatin 80 mg daily or placebo on stroke was evaluated in 4731 patients who had a stroke or transient ischemic attack (TIA) within the preceding 6 months and no history of coronary heart disease (CHD). Lipitor is used to lower lipids known as cholesterol and triglycerides in the blood when a low fat diet and life style changes on their own have failed.
In rats, plasma concentrations of atorvastatin are similar to those in milk.